Ectopic CD11c Drives SMAD3-Mediated Aberrant Antigen Presentation and Epithelial-Mesenchymal Transition in Esophageal Squamous Cell Carcinoma - PubMed
4 days ago
- #ESCC
- #CD11c
- #Immunotherapy
- Ectopic CD11c expression in ESCC leads to immune evasion and malignant phenotypes.
- CD11c impairs antigen presentation and promotes EMT via SMAD3 phosphorylation.
- CD11c suppresses CD80/CD86 and enhances immunosuppressive CD4+ T cell responses.
- Combined anti-phospho-SMAD3 therapy can rescue resistance to anti-PD-L1 in ESCC.
- Targeting the CD11c-SMAD3 axis may improve immunotherapy outcomes in ESCC patients.